- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Optimizing Management of Atopic Dermatitis and Alopecia Areata: From First-Line to Second-Line Treatments and Safety Protocols
Author(s):
Robert Bruce Posnick, MD, examines a case of a 55-year-old female patient with a 50-year history of atopic dermatitis, comorbid asthma, and severe alopecia areata, presenting with recurrent patches throughout her body, predominantly affecting her face, hands, trunk, arms, legs, and eyelids.
Video Player is loading.
- What is your impression of this case? What challenges does this case present with, if any?
- What co-morbidities do you typically see with Atopic Dermatitis?
- Given her history, would you treat systemically? If so, oral JAK or injectable biologic?
- Would you consider a topical JAK, ie ruxolitinib? If so, any concern using topical JAK in combo with systemic therapy, if so which ones?
Related Videos
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Differentiating Between JAK Inhibitors in Clinical Practice
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Laboratory Monitoring with Oral JAK Inhibitors
Related Content
